Skip to content
DataLookout
Menu

αHLA-G Exo-01NCT07219940

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words
    • Enrollment closed, study ongoing
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Minor Site contact updatedv4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2025 to Dec 1, 2025
    • Site details revised
    v3
  4. Minor Start date: Oct 2025 to Nov 2025v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse event (AE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Incidence of serious adverse event (SAE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Incidence of treatment-emergent adverse event (TEAE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Abnormalities in physical examination (PE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Abnormalities in ECG
Timeframe: From start until 3 weeks after the last dose of SOB100

Arms and interventions

SOB100Experimental

Drugs: SOB100

Sites

1 site in 1 country

  • Parexel International - Baltimore Early Phase Clinical UnitBaltimore, Maryland, United States